Breaks Categories: News

ThursdayOct 31, 2024 9:10 am

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO Details Promising Phase 3 Path for Alzheimer’s Treatment on The BioMedWire Podcast

Annovis Bio (NYSE: ANVS) led by Founder, President and CEO Dr. Maria Maccecchini, shares exciting developments regarding its pioneering Alzheimer’s and Parkinson’s drug candidate, buntanetap. In her interview on IBN’s BioMedWire Podcast, Dr. Maccecchini discusses Annovis Bio’s recent FDA clearance to proceed with pivotal Phase 3 trials for early-stage Alzheimer’s patients, a critical step toward potential market approval. Highlighting buntanetap’s unique mechanism that targets multiple neurotoxic proteins, Dr. Maccecchini explains the potential for superior outcomes compared to existing therapies, emphasizing the drug’s demonstrated short-term efficacy and differentiated approach in neurodegenerative treatment. To view the full press release, visit https://ibn.fm/NURbX About…

Continue Reading

WednesdayOct 30, 2024 3:28 pm

BioMedNewsBreaks — Polyrizon Ltd. (NASDAQ: PLRZ) Secures $4.2M in Initial Public Offering

  Polyrizon (NASDAQ: PLRZ), a development stage biotech company specializing in the development of innovative medical device hydrogels, has announced the closing of its underwritten initial public offering of 958,903 units at a combined public offering price of $4.38 per unit. Polyrizon secured aggregate gross proceeds of $4.2 million, prior to deducting underwriting discounts and offering expenses. In addition, PLRZ has granted Aegis Capital Corp. a 45-day option to purchase up to 143,835 additional units, equal to 15% of the number of ordinary shares sold in the offering, solely to cover over-allotments, if any. If Aegis exercises the option in…

Continue Reading

ThursdayOct 24, 2024 10:24 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures $3 Million in Registered Direct Offering

  CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for cancers affecting the brain and central nervous system, has announced that it has entered into securities purchase agreements with institutional investors to raise approximately $3 million. The funding will come from the sale of 17,647,060 shares of common stock, priced at $0.17 per share, in a registered direct offering. The proceeds will be used for general corporate purposes and working capital. A.G.P./Alliance Global Partners is acting as the sole placement agent for the transaction, which is expected to close today, Oct. 24, 2024, pending customary conditions. To…

Continue Reading

ThursdayOct 24, 2024 9:00 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Wins 2024 Digital Health Hub Award for Innovation in Cardiac Care

HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care, was recognized with the 2024 Digital Health Hub Rising Star award in the ‘Home Health Diagnostic’ category at the HLTH global healthcare conference. The award highlights HeartBeam’s innovative vector-based technology, which captures heart electrical signals in three dimensions to provide detailed cardiac insights. CEO Rob Eno emphasized the importance of timely care in cardiac health, praising the team’s efforts in developing a cable-free, credit card-sized ECG device, currently under FDA review, as a step towards personalized, AI-driven cardiac care. To view the full press release, visit https://ibn.fm/1ZLrn About HeartBeam…

Continue Reading

TuesdayOct 22, 2024 11:26 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present Key Alzheimer’s Research at CTAD Conference in Madrid

Annovis Bio (NYSE: ANVS) will showcase its latest scientific findings on its Alzheimer’s drug candidate, Buntanetap, at the 17th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference in Madrid from Oct. 29 to Nov. 1, 2024. The company will present two posters highlighting Buntanetap’s efficacy in early Alzheimer’s patients and its impact on reducing neurotoxic proteins, improving axonal integrity, and enhancing neuronal function. These results further support Annovis Bio's ongoing efforts to develop transformative therapies for neurodegenerative diseases. To view the full press release, visit https://ibn.fm/2vnw1 About Annovis Bio Inc. Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration…

Continue Reading

TuesdayOct 22, 2024 9:00 am

BioMedNewsBreaks – HealthLynked Corp. (OTC: HLYK) Partners With 3X4 Genetics to Enhance Personalized Healthcare Services

HealthLynked Corp. (OTCQB: HLYK) has announced a strategic partnership with 3X4 Genetics to offer personalized genetic testing to its members, advancing its mission to provide tailored and predictive healthcare solutions. The collaboration will allow HealthLynked members to access 3X4 Genetics' sophisticated genetic insights, empowering them to make informed health decisions and receive more personalized care. This partnership marks a key step in HealthLynked's broader strategy of integrating cutting-edge technologies to improve healthcare outcomes and expand its service offerings. To view the full press release, visit https://ibn.fm/GL0d6 About HealthLynked Corp. HealthLynked Corp. is committed to improving global healthcare by facilitating the…

Continue Reading

TuesdayOct 15, 2024 1:54 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Receives FDA Clearance for Pivotal Phase 3 Alzheimer’s Trial, Launch Set for Early 2025

  Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), announced today that the U.S. Food and Drug Administration (“FDA”) has granted clearance to proceed with pivotal Phase 3 studies for buntanetap in early-stage Alzheimer’s patients. This decision follows a successful End-of-Phase 2 meeting held on Oct. 10, 2024, where Annovis and the FDA aligned on the next steps for advancing buntanetap toward New Drug Application (“NDA”) submissions. The Phase 3 program will consist of two trials: a 6-month study aimed at confirming…

Continue Reading

TuesdayOct 15, 2024 10:15 am

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Files Patent for ‘Gamechanging’ AI-Powered Healthcare Assistant

HealthLynked (OTCQB: HLYK), a leader in connecting patients, doctors and healthcare data, has filed a patent with the United States Patent and Trademark Office (“USPTO”). According to the announcement, the nonprovisional patent covers ARi, an innovative artificial intelligence (“AI”)-powered personal healthcare assistant and is designed to provide long-term protection for Ari and the company. HealthLynked noted that last year it filed a provisional patent following the release of Generative Pretrained Transformers (“GPT”) and Large Language Models (“LLMs”) from OpenAI. “At HealthLynked, we are committed to empowering patients to take control of their health,” said HealthLynked CEO Dr. Michael Dent in…

Continue Reading

ThursdayOct 10, 2024 1:08 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Management, Dr. Samuel Goldlust Participate in Virtual Investor KOL Connect Segment

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company announced Thursday morning that it participated in a Virtual Investor KOL Connect segment. Members of the company’s management team and Dr. Samuel Goldlust, who previously served as an investigator in the company’s global potentially pivotal study of Berubicin, joined the segment to provide a corporate update, discuss the unmet need in glioblastoma multiforme (“GBM”), and highlight the opportunity for the company. To access the segment, visit https://ibn.fm/V1eC1 To view the full…

Continue Reading

WednesdayOct 09, 2024 1:35 pm

BioMedNewsBreaks — Oragenics, Inc. (NYSE American: OGEN) Reports on Lead Candidate Drug Development, ‘Urgency’ to Advance First-in-Class Concussion Treatment

Oragenics (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, has released a corporate update. Highlights of shareholder report include an overview of key milestones reached this year as the company has developed its lead candidate, ONP-002, a first-in-class neurosteroid designed for the treatment of concussions. Those milestones include strengthening the company’s clinical leadership, preparing for a phase 2 clinical trial, successful cardiotoxicity testing and required genotoxicity studies and establishing a key partnership with Avance Clinical, a leading contract research organization (“CRO”). “Our mission is to address significant unmet medical needs by developing cutting-edge therapies,”…

Continue Reading